Diseases which may be prevented or cured by means of therapeutic fasting and caloric restriction  
(experimental and clinical evidence: click to see scientific report)

» arthritis rheumatoid
» asthma
» cardiovascular diseases
» cholecystitis and gout
» chronic fatigue syndrome
» diabetes
» digestive system diseases
» epilepsy
» glomerulonephritis
» hypertension
» infections
» infertility
» Low immunity
» neurodegenerative disorders
» obesity
» ovarian tumors
» pancreatitis
» psoriasis
» psychiatric disorders
» respiratory system diseases
» skin disorders
» spinal column diseases
» thrombophlebitis
» tumours, cancer
» uterine fibroids
» Complications in fasting
» Safety of fating
» sarcoidosis
Anti-Aging Therapy
Fasting / low-calorie program on Adriatic Sea Coast
Cholesterol drug might treat learning disabilities
 
 09.11.2005
Lovastatin, a widely used cholesterol-lowering drug, reverses common learning disabilities in mice, offering the first hope for a treatment of the problem in humans, University of California, Los Angeles, researchers reported Monday.
Three separate human trials in children and adults will begin at UCLA and other U.S. and European locations within weeks, said Dr. Alcino Silva, a neurobiologist at UCLA and the lead author of a paper appearing in the journal Current Biology.
"Currently, there are no treatment options for these people," Silva said. "That's why our findings are so exciting from a clinical perspective."
Lovastatin, trade-named Mevacor, is one of a family of drugs known collectively as statins that have revolutionized the treatment of high cholesterol. The drugs, introduced in the 1990s, are taken daily by millions of people at risk for heart disease and other problems and have been widely recognized as safe.
The learning problems studied by the researchers were caused by a genetic defect called neurofibromatosis 1, the most common genetic cause of learning disabilities. It affects one in every 3,000 to 4,000 people. The learning disabilities include poor attention spans, difficulties in carrying out tasks involving spatial abilities and problems learning new tasks.
The key to the discovery is a protein called Ras, which regulates how brain cells communicate.
Silva and his colleagues had previously shown that the genetic mutations associated with neurofibromatosis 1 lead to an excess production of Ras, which inhibits the brain's ability to record newly learned information.
The team searched for a drug that could interfere with the excess Ras but had little success, Silva said. Then one of his former students, Steve Kushner, learned during a medical-school rotation that statins can interfere with Ras.
"He came back into my office late at night and said, 'I think I have something that might work,' " Silva said.
Statins interfere with Ras by reducing the level of fats found in blood, known as lipids, which the brain protein needs to carry out its function.
Postdoctoral fellow Weidong Li in Silva's lab tested the theory using specially bred rats that have the neurofibromatosis 1 mutation and have previously been shown to have learning problems similar to those seen in humans with the disorder.
In one test, he trained adult mice with the mutation to follow a blinking light to obtain a food reward. After the animals received the drug, their performance improved by 30 percent, so that they outperformed normal mice.
Two other tests provided similar results.
"This is mind-blowing," Silva said. "We think we have a real, fundamental reason to be optimistic. ... Now we are ready to go and treat the human disorder."

«« Back